

Product Information

5-Bromo-4-chloro-3-indolyl phosphate disodium salt

B6149

Product Description


CAS Registry Number: 102185-33-1

Synonyms: BCIP® disodium salt, X-phosphate disodium salt

Molecular Formula: C₈H₄BrClNO₄P • 2Na

Formula Weight: 370.43

Structure:



5-Bromo-4-chloro-3-indolyl phosphate (BCIP®) and nitro blue tetrazolium (NBT) are commonly used for colorimetric detection of alkaline phosphatase-labeled molecules. The BCIP®/NBT substrate system is versatile and functions in various applications, including Northern, Southern, and Western blotting, *in situ* hybridization, and immunohistochemistry.¹⁻⁸

BCIP® disodium salt is soluble in water. A BCIP® disodium salt stock solution may be used in combination with NBT and a reaction buffer to form a substrate solution for alkaline phosphatase. When incubated with alkaline phosphatase, this substrate system produces an insoluble NBT diformazan product that is easily observable with its purple color, per the general reaction scheme in Figure 1.

BCIP® disodium salt is prepared synthetically. Several publications,⁹⁻¹⁷ theses,¹⁸ and dissertations¹⁹⁻²⁴ have cited use of product B6149 in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

BCIP® disodium salt is soluble in water at 50 mg/mL. It is insoluble in DMF.

Storage/Stability

Store BCIP® disodium salt at -20 °C, protected from light and moisture.

Procedure

Sample Protocol for NBT/BCIP® System for Detection of Alkaline Phosphatase

This protocol may be used for such applications as Western blotting.

1. Prepare Substrate Buffer (0.1 M Tris, 100 mM NaCl, 5 mM MgCl₂, pH 9.5). Adjust pH with HCl.
2. Prepare NBT (Cat. No. N6639) stock solution at 10 mg/mL in water.
3. Prepare BCIP® disodium salt stock solution at 50 mg/mL in water.
4. Prepare BCIP®/NBT Substrate Solution by adding 33 µL of 50 mg/mL BCIP® disodium salt stock solution and 330 µL of 10 mg/mL NBT stock solution to 10 mL of Substrate Buffer.
5. Rinse specimens incubated with an alkaline phosphatase conjugate in a wash buffer (**non-phosphate**) before treatment with the BCIP®/NBT Substrate Solution. Cover the entire specimen with the reagent during color development.
6. Incubate the specimen at room temperature with the BCIP®/NBT Substrate Solution for ~10 minutes. Specimens and procedure may affect the length of time needed for color development.
7. Monitor color development to avoid over-development. Stop color development by rinsing the specimen with distilled water.

References

1. Blake, M.S. *et al.*, *Anal. Biochem.*, **136**(1), 175-179 (1984).
2. Green, F.J. (ed.), *The Sigma-Aldrich Handbook of Stains, Dyes & Indicators*. Aldrich Chemical Co., (Milwaukee, WI), p. 523 (1990).
3. Horwitz, J.P. *et al.*, *J. Med. Chem.*, **9**(3), 447 (1966).
4. Knecht, D.A., and Dimond, R.L., *Anal. Biochem.*, **136**(1), 180-184 (1984).
5. Leary, J.J. *et al.*, *Proc. Natl. Acad. Sci. USA*, **80**(13), 4045-4049 (1983).
6. McGadey, J., *Histochemie*, **23**(2), 180-184 (1970).
7. Meltzer, J.C. *et al.*, *J. Histochem. Cytochem.*, **45**(4), 599-610 (1997).
8. Walters, C. *et al.*, *J. Clin. Pathol.*, **50**(9), 749-754 (1997).
9. Høyer, P.E., and Kirkeby, S., *J. Histochem. Cytochem.*, **44**(8), 855-863 (1996).
10. Pagnussat, G.C. *et al.*, *Physiologia Plantarum*, **108**(4), 337-344 (2000).
11. Weglarz, T.C., and Sandgren, E.P., *Proc. Nat. Acad. Sci. USA*, **97**(23), 12595-12600 (2000).
12. Hagemann, T.L. *et al.*, *J. Neurosci.*, **26**(43), 11162-11173 (2006).
13. Schreiner, P., *J. Exp. Microbiol. Immunol.*, **13**, 93-99 (2009).
14. Qi, M. *et al.*, *J. Bacteriol.*, **193**(10), 2498-2509 (2011).
15. Wu, X. *et al.*, *BMC Microbiol.*, **11**, 87 (2011).
16. Cui, Z.-K. *et al.*, *Nat. Commun.*, **10**(1), 3523 (2019).
17. Schepler, H. *et al.*, *Theranostics*, **12**(1), 18-34 (2022).
18. Antonakou, Vasiliki, "Lhx6 controls cIN development on a stage and IN-subtype specific manner". University of Athens, M.Sc. thesis, p. 14 (2019).
19. McKeand, Jacqueline B., "Aspects of the immunobiology of *Dictyocaulus viviparus* infection". University of Glasgow, Ph.D. dissertation, p. 50 (1992).
20. Sasselli, Valentina, "The potential role of Rac signalling and the Planar Cell Polarity pathway in wiring of the Enteric Nervous System". University College London, Ph.D. dissertation, p. 95 (2011).
21. Hamilton, Andrew, "Determination of the Structural Requirements for Modification of Vascular Endothelial Growth Factor Angiogenic Activity by Heparan Sulfate Oligosaccharides". University of Manchester, Ph.D. dissertation, pp. 79, 216 (2011).
22. Kalaitzidou, Melania, "The role of SATB1 in medial ganglionic eminence-derived cortical interneuron differentiation". University College London, Ph.D. dissertation, p. 99 (2014).
23. Velasco, Vera Marjorie Elauria, "Traits underlying phosphorus use by the extremophyte *Eutrema salsugineum*". McMaster University, Ph.D. dissertation, p. 41 (2017).
24. Matheus, Friederike, "The role of *Additional sex combs-like* genes in human pluripotent stem cell differentiation and congenital disorders". Ludwig-Maximilians-Universität zu München, Dr. rer. nat. Dissertation, p. 59 (2018).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty


The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.



Figure 1. BCIP®/NBT Reactions



Troubleshooting Guide for Western Blotting

Problem	Suggestion
The background is too high.	Use a blocking step prior to application of the primary antibody. Normal serum (10% v/v) from the same species as the second antibody generally produces the best results.
	- Additional blocking agents for immunoblotting are 10% BSA, 0.05% TWEEN® 20, or 3% non-fat dried milk. Note: Do not use milk as a blocking agent when using avidin-biotin systems.
	Decrease staining time.
	Titer the conjugate to optimize working dilution
No color develops or the color is too faint.	Adjust the concentration of the primary antibody
	Adjust the concentration of the secondary antibody
	Determine if the enzyme conjugate is active.
	Consider using an amplifying system such as avidin-biotin.
	Increase the staining time.
	Adjust the transfer time of the samples to the nitrocellulose membrane
	Increase the amount of sample.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

B6149pis Rev 02/22 RBG,KTA,MAM,GCY

MERCK